Maynooth University spin-out Profector Life Sciences enters into collaboration deal with Adapt Pharma.

Ireland-based Profector Life Sciences has entered into a collaboration deal with Adapt Pharma, said to be worth €2m ($2.37m).

Profector, established in 2011, is a spin-out of National University of Ireland, Maynooth, launched after eight years of research and development into gene and cellular delivery technology platforms.

Michael Maguire, CEO of Profector, stated, “My team and I are excited about bringing Adapt’s business development and pharmaceutical sector expertise to our suite of capabilities. With Adapt, we will work to refine…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?